980 related articles for article (PubMed ID: 21988181)
21. Self-assembly of DNA-based drug delivery nanocarriers with rolling circle amplification.
Ouyang X; Li J; Liu H; Zhao B; Yan J; He D; Fan C; Chao J
Methods; 2014 May; 67(2):198-204. PubMed ID: 23747336
[TBL] [Abstract][Full Text] [Related]
22. Self-assembled DNA nanocentipedes as multivalent vehicles for enhanced delivery of CpG oligonucleotides.
Li W; Luo L; Huang J; Wang Q; Liu J; Xiao X; Fang H; Yang X; Wang K
Chem Commun (Camb); 2017 May; 53(40):5565-5568. PubMed ID: 28475186
[TBL] [Abstract][Full Text] [Related]
23. Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway.
Schwartz DA; Wohlford-Lenane CL; Quinn TJ; Krieg AM
J Immunol; 1999 Jul; 163(1):224-31. PubMed ID: 10384120
[TBL] [Abstract][Full Text] [Related]
24. Alpha 2-macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism.
Anderson RB; Cianciolo GJ; Kennedy MN; Pizzo SV
J Leukoc Biol; 2008 Feb; 83(2):381-92. PubMed ID: 17967834
[TBL] [Abstract][Full Text] [Related]
25. Uniform small graphene oxide as an efficient cellular nanocarrier for immunostimulatory CpG oligonucleotides.
Sun J; Chao J; Huang J; Yin M; Zhang H; Peng C; Zhong Z; Chen N
ACS Appl Mater Interfaces; 2014 May; 6(10):7926-32. PubMed ID: 24712847
[TBL] [Abstract][Full Text] [Related]
26. Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles.
Malyala P; O'Hagan DT; Singh M
Adv Drug Deliv Rev; 2009 Mar; 61(3):218-25. PubMed ID: 19168103
[TBL] [Abstract][Full Text] [Related]
27. Smart drug delivery nanocarriers with self-assembled DNA nanostructures.
Li J; Fan C; Pei H; Shi J; Huang Q
Adv Mater; 2013 Aug; 25(32):4386-96. PubMed ID: 23765613
[TBL] [Abstract][Full Text] [Related]
28. Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9).
Iliev AI; Stringaris AK; Nau R; Neumann H
FASEB J; 2004 Feb; 18(2):412-4. PubMed ID: 14688201
[TBL] [Abstract][Full Text] [Related]
29. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect.
Wiradharma N; Tong YW; Yang YY
Biomaterials; 2009 Jun; 30(17):3100-9. PubMed ID: 19342093
[TBL] [Abstract][Full Text] [Related]
30. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.
Kandimalla ER; Bhagat L; Li Y; Yu D; Wang D; Cong YP; Song SS; Tang JX; Sullivan T; Agrawal S
Proc Natl Acad Sci U S A; 2005 May; 102(19):6925-30. PubMed ID: 15860583
[TBL] [Abstract][Full Text] [Related]
31. Specific siRNA downregulated TLR9 and altered cytokine expression pattern in macrophage after CpG DNA stimulation.
Qiao B; Li B; Yang X; Zhang H; Chu Y; Wang Y; Xiong S
Cell Mol Immunol; 2005 Apr; 2(2):130-5. PubMed ID: 16191419
[TBL] [Abstract][Full Text] [Related]
32. Characterization of immunostimulatory CpG-rich sequences from different Bifidobacterium species.
Ménard O; Gafa V; Kapel N; Rodriguez B; Butel MJ; Waligora-Dupriet AJ
Appl Environ Microbiol; 2010 May; 76(9):2846-55. PubMed ID: 20208019
[TBL] [Abstract][Full Text] [Related]
33. Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development.
Yamamoto S; Yamamoto T; Nojima Y; Umemori K; Phalen S; McMurray DN; Kuramoto E; Iho S; Takauji R; Sato Y; Yamada T; Ohara N; Matsumoto S; Goto Y; Matsuo K; Tokunaga T
Jpn J Infect Dis; 2002 Apr; 55(2):37-44. PubMed ID: 12082305
[TBL] [Abstract][Full Text] [Related]
34. CpG DNA and LPS induce distinct patterns of activation in human monocytes.
Hartmann G; Krieg AM
Gene Ther; 1999 May; 6(5):893-903. PubMed ID: 10505115
[TBL] [Abstract][Full Text] [Related]
35. Immunostimulatory CpG-modified plasmid DNA enhances IL-12, TNF-alpha, and NO production by bovine macrophages.
Shoda LK; Kegerreis KA; Suarez CE; Mwangi W; Knowles DP; Brown WC
J Leukoc Biol; 2001 Jul; 70(1):103-12. PubMed ID: 11435492
[TBL] [Abstract][Full Text] [Related]
36. DNA nanostructure-based imaging probes and drug carriers.
Zhan P; Jiang Q; Wang ZG; Li N; Yu H; Ding B
ChemMedChem; 2014 Sep; 9(9):2013-20. PubMed ID: 25045126
[TBL] [Abstract][Full Text] [Related]
37. Functional DNA nanostructures for theranostic applications.
Pei H; Zuo X; Zhu D; Huang Q; Fan C
Acc Chem Res; 2014 Feb; 47(2):550-9. PubMed ID: 24380626
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant activity of CpG oligodeoxynucleotides.
Klinman DM
Int Rev Immunol; 2006; 25(3-4):135-54. PubMed ID: 16818369
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
Ishii KJ; Gursel I; Gursel M; Klinman DM
Curr Opin Mol Ther; 2004 Apr; 6(2):166-74. PubMed ID: 15195929
[TBL] [Abstract][Full Text] [Related]
40. DNA and its cationic lipid complexes induce CpG motif-dependent activation of murine dendritic cells.
Yoshinaga T; Yasuda K; Ogawa Y; Nishikawa M; Takakura Y
Immunology; 2007 Mar; 120(3):295-302. PubMed ID: 17199803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
